Genomma Lab Intl Sab Ord (GNMLF) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, ladies and gentlemen. Thank you for joining Genoma Labs' fourth quarter 2024 earnings conference call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. As a reminder, this meeting is being recorded and will be available for replay on the Investor Relations section of Genoma's website following the call. I'll now turn the call over to Christian Ibanez, Genoma's Head of Investor Relations. Please, go ahead. Thank you, and welcome, everyone. On today's call are Marcos Barbieri, Chief Executive Officer, and Antonio Zamora, Chief Financial Officer. Before we get started, I'd like to remind you that the remarks today will include forward-looking statements, such as the company's financial guidance and expectations, including long-term objectives and forecasts, as well as expectations regarding Genoma's business, assets, products, strategies, demands, and markets. These statements are subject to risks and uncertainties that could cause actual results to differ materially. They are also based on assumptions as of today, and the company undertakes no obligation to update them as a result of new information or future events. Let me now turn the call over to Mr. Marcos Calderi. Good morning, everyone, and thank you, Chris. I am thrilled to share our strong Q4 and full year 2024 results. 2024 was an outstanding year for the company, marked by exceptional profitability gains and steady growth across key markets. Each line of the P&L showed increasing momentum, with EBITDA growing faster than sales and net income outpacing both. We surpassed our internal targets across all key metrics. Next sales grew 32.4% in Q4 and 13% for the full year, driven by strong performance in key markets, including Mexic...